<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="182842">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00714142</url>
  </required_header>
  <id_info>
    <org_study_id>UW HS IRB 2008-0097</org_study_id>
    <secondary_id>DK58466</secondary_id>
    <nct_id>NCT00714142</nct_id>
  </id_info>
  <brief_title>Renal Blood Flow Measurement With Positron Emission Tomography (PET)</brief_title>
  <official_title>Renal Blood Flow Measurement With PET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Proportional Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Proportional Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two investigational chemical tracers, 62Cu-ethylglyoxal bis(thiosemicarbazone) (62Cu-ETS)
      and 15O-water, will be used in this study to look at how blood moves through the kidneys.
      The purpose of the study is to see if 62Cu-ETS is effective in showing the blood supply to
      the kidneys compared to 15O-water. The tracer mixes with the blood and moves through the
      body. Using positron emission tomography (PET scan) the researchers can see the tracer and
      can learn more about how the blood moves through the kidneys. The study invites participants
      who are healthy, without any heart or kidney disease, patients who have kidney disease that
      require dialysis, and patients who may have a blockage in one of the arteries supplying
      blood to the kidneys.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">April 2009</completion_date>
  <primary_completion_date type="Anticipated">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Obtain preliminary information on efficacy for quantification of regional renal perfusion in two target clinical populations with a full range of renal disease using 150-water PET and 62Cu-ETS PET</measure>
    <time_frame>one day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the safety of the drug 62Cu-ETS through expansion to two target patient populations and increase the size of the normal subjects group</measure>
    <time_frame>one day</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Renal Failure</condition>
  <condition>Renal Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normal volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Renal failure patients on dialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Renal artery stenosis patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>62Cu-ethylglyoxal bis(thiosemicarbazone)</intervention_name>
    <description>15-25 mCi, IV</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>15O-water</intervention_name>
    <description>10-20 mCi, IV</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>PET Scan</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Arm 1.

        Inclusion Criteria:

          -  males and females, age 18-40 years

          -  willingness to provide written informed consent

        Exclusion Criteria:

          -  history of coronary artery disease (CAD)

          -  history of renal disease

          -  risk factors for cardiac disease, renal disease, or atherosclerosis, including
             diabetes mellitus, hypertension, tobacco abuse, hyperlipidemia, family history of CAD
             or chronic renal failure

          -  history of liver disease or other significant disease

          -  pregnant females

        Arm 2.

        Inclusion Criteria:

          -  males and females, age &gt; 18 years

          -  active hemodialysis or peritoneal dialysis for at least six months

          -  any etiology of chronic renal failure except active glomerular nephritis

          -  presence of two kidneys

          -  willingness to provide written informed consent

        Exclusion Criteria:

          -  decompensated heart failure (subjects must be on stable medical therapy for one
             month)

          -  any previous renal transplant (subjects may be on renal transplant waiting list)

          -  history of liver disease

          -  pregnant females

        Arm 3.

        Inclusion Criteria:

          -  males and females, age &gt; 18 years

          -  documented evidence of renal artery stenosis equivalent to a 75% stenosis by one of
             the following clinical tests: MRA, Doppler, Renal Angiogram, Abnormal captopril renal
             scan

          -  evidence of renal insufficiency with serum creatinine &gt;= 1.3 mg/dL

          -  presence of two kidneys

          -  willingness to provide written informed consent

        Exclusion Criteria:

          -  revascularization of stenotic renal artery

          -  decompensated heart failure (subjects must be on stable medical therapy for one
             month)

          -  any previous renal transplant (subjects may be on renal transplant waiting list)

          -  history of liver disease

          -  pregnant females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey L Lacy, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Proportional Technologies, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles K Stone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey L Lacy, PhD</last_name>
    <phone>713-747-7324</phone>
    <phone_ext>11</phone_ext>
    <email>jlacy@proportionaltech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Wisconsin - Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassondra Vander Ark, RN, MS, CCRC</last_name>
      <phone>608-265-0612</phone>
      <email>cav@clinicaltrials.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Charles K Stones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <lastchanged_date>September 2, 2008</lastchanged_date>
  <firstreceived_date>July 10, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Jeffrey L. Lacy, President</name_title>
    <organization>Proportional Technologies, Inc.</organization>
  </responsible_party>
  <keyword>Renal blood flow</keyword>
  <keyword>PET imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Artery Obstruction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
